Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Sun, Weijing ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Antiangiogenic; Colorectal cancer; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN; BEVACIZUMAB; BRIVANIB ALANINATE; CEDIRANIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR; INTEGRIN; IRINOTECAN; NOTCH RECEPTOR; OXALIPLATIN; PLACEBO; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; REGORAFENIB; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ABDOMINAL PAIN; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ASTHENIA; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL PROLIFERATION; COLORECTAL CANCER; COMPETITIVE INHIBITION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REGIMEN; DRUG ERUPTION; FATIGUE; GASTROINTESTINAL PAIN; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH SQUAMOUS CELL CARCINOMA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SKIN ULCER; SMOOTH MUSCLE FIBER; STOMATITIS; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84867235528     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-63     Document Type: Review

References (85)

1. Angiogenic factors. Folkman J, Klagsbrun M, Science 1987 235 442 447 10.1126/science.2432664 2432664
2. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Jain RK, Science 2005 307 58 62 10.1126/science.1104819 15637262
3. Tumor angiogenesis: therapeutic implications. Folkman J, N Engl J Med 1971 285 1182 1186 10.1056/NEJM197111182852108 4938153
4. Vascular endothelial growth factor: basic science and clinical progress. Ferrara N, Endocr Rev 2004 25 581 611 10.1210/er.2003-0027 15294883
5. VEGF-targeted therapy: mechanisms of anti-tumour activity. Ellis LM, Hicklin DJ, Nat Rev Cancer 2008 8 579 591 10.1038/nrc2403 18596824
6. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ, Science 1999 284 1994 1998 10.1126/science.284.5422.1994 10373119
7. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Konerding MA, Malkusch W, Klapthor B, van Ackern C, Fait E, Hill SA, Parkins C, Chaplin DJ, Presta M, Denekamp J, Br J Cancer 1999 80 724 732 10.1038/sj.bjc.6690416 10360650
8. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM, Am J Pathol 2002 160 985 1000 10.1016/S0002-9440(10)64920-6 11891196
9. Openings between defective endothelial cells explain tumor vessel leakiness. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM, Am J Pathol 2000 156 1363 1380 10.1016/S0002-9440(10) 65006-7 10751361
10. Pathology: cancer cells compress intratumour vessels. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK, Nature 2004 427 695 10.1038/427695a 14973470
11. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Boucher Y, Baxter LT, Jain RK, Cancer Res 1990 50 4478 4484 2369726
12. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Fukumura D, Duda DG, Munn LL, Jain RK, Microcirculation 2010 17 206 225 10.1111/j.1549-8719.2010.00029.x 20374484
13. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Helmlinger G, Yuan F, Dellian M, Jain RK, Nat Med 1997 3 177 182 10.1038/nm0297-177 9018236
14. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM, Am J Pathol 2003 163 1801 1815 10.1016/S0002-9440(10)63540-7 14578181
15. Genes that distinguish physiological and pathological angiogenesis. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B, Cancer Cell 2007 11 539 554 10.1016/j.ccr.2007.04.017 17560335
16. Genes expressed in human tumor endothelium. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW, Science 2000 289 1197 1202 10.1126/science.289. 5482.1197 10947988
17. Tumor-associated endothelial cells with cytogenetic abnormalities. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M, Cancer Res 2004 64 8249 8255 10.1158/0008-5472.CAN-04-1567 15548691
18. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Dvorak HF, J Clin Oncol 2002 20 4368 4380 10.1200/JCO.2002.10.088 12409337
19. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S, Erratum in: Proc Natl Acad Sci U S A 1997 94 1603 Proc Natl Acad Sci U S A 1996, 93:11675-11680.
20. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG, Proc Natl Acad Sci U S A 1991 88 9267 9271 10.1073/pnas.88.20. 9267 1924389
21. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U, Proc Natl Acad Sci U S A 1996 93 2576 2581 10.1073/pnas.93.6.2576 8637916
22. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K, Erratum in: EMBO J 1996 15 1751 EMBO J 1996, 15:290-298. 8612600
23. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M, Cell 1998 92 735 745 10.1016/S0092-8674(00)81402-6 9529250
24. Neuropilin-1 is a placenta growth factor-2 receptor. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, Neufeld G, J Biol Chem 1998 273 22272 22278 10.1074/jbc.273.35.22272 9712843
25. The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Neufeld G, Kessler O, Herzog Y, Adv Exp Med Biol 2002 515 81 90 10.1007/978-1-4615-0119-0-7 12613545
26. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Cao Y, Sci Signal 2009 2 e1 10.1126/scisignal.259re1 19244214
27. Tumor angiogenesis. Kerbel RS, N Engl J Med 2008 358 2039 2049 10.1056/NEJMra0706596 18463380
28. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Kut C, Mac Gabhann F, Popel AS, Br J Cancer 2007 97 978 985 10.1038/sj.bjc.6603923 17912242
29. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Takahashi T, Ueno H, Shibuya M, Oncogene 1999 18 2221 2230 10.1038/sj.onc. 1202527 10327068
30. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. Meadows KN, Bryant P, Pumiglia K, J Biol Chem 2001 276 49289 49298 10.1074/jbc.M108069200 11682481
31. Targeting the ANGPT-TIE2 pathway in malignancy. Huang H, Bhat A, Woodnutt G, Lappe R, Nat Rev Cancer 2010 10 575 585 10.1038/nrc2894 20651738
32. Integrins in angiogenesis and cancer. Weis SM, Cheresh DA, Cold Spring Harb Perspect Med 2011 1 006478 22229119
33. Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Zheng W, Tammela T, Yamamoto M, Anisimov A, Holopainen T, Kaijalainen S, Karpanen T, Lehti K, Ylä-Herttuala S, Alitalo K, Blood 2011 118 1154 1162 10.1182/blood-2010-11-317800 21566091
34. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A, Aranda E, Miura N, Ylä-Herttuala S, Fruttiger M, Mäkinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K, Nat Cell Biol 2011 13 1202 1213 10.1038/ncb2331 21909098
35. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams RH, Nature 2012 484 110 114 10.1038/nature10908 22426001
36. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Fischer C, Mazzone M, Jonckx B, Carmeliet P, Nat Rev Cancer 2008 8 942 956 10.1038/nrc2524 19029957
37. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M, Proc Natl Acad Sci U S A 1998 95 9349 9354 10.1073/pnas.95.16.9349 9689083
38. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM, Curr Biol 2003 13 1721 1727 10.1016/j.cub.2003.09.002 14521839
39. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. Yi ZY, Feng LJ, Xiang Z, Yao H, J Invest Surg 2011 24 67 76 10.3109/08941939.2010. 542272 21345006
40. Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H, Oral Oncol 2004 40 13 20 14662410
41. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB, J Pathol 2001 193 325 332 10.1002/path.814 11241411
42. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, Lorentz P, Jeltsch M, Alitalo K, Eriksson U, Christofori G, Pietras K, PLoS One 2010 5 14109 10.1371/journal.pone.0014109 21124841
43. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, Kumar A, Rissanen TT, Wang B, Nagai N, Fons P, Fariss R, Zhang Y, Wawrousek E, Tansey G, Raber J, Fong GH, Ding H, Greenberg DA, Becker KG, Herbert JM, Nash A, Yla-Herttuala S, Cao Y, Watts RJ, Li X, Proc Natl Acad Sci U S A 2009 106 6152 6157 10.1073/pnas.0813061106 19369214
44. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG, Nat Med 2001 7 575 583 10.1038/87904 11329059
45. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Roy H, Bhardwaj S, Babu M, Jauhiainen S, Herzig KH, Bellu AR, Haisma HJ, Carmeliet P, Alitalo K, Ylä-Herttuala S, Hum Gene Ther 2005 16 1422 1428 10.1089/hum.2005.16.1422 16390273
46. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N, Bais C, Proc Natl Acad Sci U S A 2011 108 11590 11595 10.1073/pnas.1109029108 21709213
47. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB, J Pathol 2003 200 183 194 10.1002/path.1339 12754739
48. Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer. Wang TB, Chen ZG, Wei XQ, Wei B, Dong WG, ANZ J Surg 2011 81 694 699 10.1111/j.1445-2197.2010.05539.x 22295309
49. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M, Nat Med 2001 7 192 198 10.1038/84643 11175850
50. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. Wu QW, She HQ, Liang J, Huang YF, Yang QM, Yang QL, Zhang ZM, BMC Cancer 2012 12 47 10.1186/1471-2407-12-47 22284579
51. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS, EMBO J 2001 20 672 682 10.1093/emboj/20.4.672 11179212
52. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, Zhang YF, Williams SP, Farnsworth RH, Chai MG, Rupasinghe TW, Tull DL, Baldwin ME, Sloan EK, Fox SB, Achen MG, Stacker SA, Cancer Cell 2012 21 181 195 10.1016/j.ccr.2011.12.026 22340592
53. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG, Nat Med 2001 7 186 191 10.1038/84635 11175849
54. Dll4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL, Cancer Res 2011 71 6073 6083 10.1158/0008-5472.CAN-11-1704 21803743
55. Avastin [bevacizumab) prescribing information South San Francisco, CA: Genentech, Inc 2012
56. Zaltrap (ziv-aflibercept) prescribing information Bridgewater, NJ: Regeneron Pharmaceuticals, Inc./sanofi-aventis U.S. LLC 2012
57. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Gerber HP, Ferrara N, Cancer Res 2005 65 671 680 15705858
58. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S, Psyrri A, Cedarbaum JM, Spriggs DR, Clin Cancer Res 2010 16 358 366 10.1158/1078-0432.CCR- 09-2103 20028764
59. VEGF-Trap: a VEGF blocker with potent antitumor effects. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS, Proc Natl Acad Sci U S A 2002 99 11393 11398 10.1073/pnas.172398299 12177445
60. A preclinical and clinical review of aflibercept for the management of cancer. Gaya A, Tse V, Cancer Treat Rev 2012 38 484 493 10.1016/j.ctrv.2011.12. 008 22264850
61. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ, Angiogenesis 2012 15 171 185 10.1007/s10456-011-9249-6 22302382
62. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG, J Clin Oncol 2010 28 780 787 10.1200/JCO.2009.23.7537 20048182
63. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S, Leukemia 2003 17 604 611 10.1038/sj.leu.2402831 12646950
64. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ, Cancer Res 1999 59 5209 5218 10537299
65. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM, Cancer 2000 89 488 499 10.1002/1097-0142(20000801)89: 3<488::AID-CNCR3>3.0.CO;2-X 10931447
66. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ, Cancer Res 2005 65 4389 4400 10.1158/0008-5472.CAN-04-4409 15899831
67. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Kratzschmar J, Heinig R, Boix O, Christensen O, Clin Cancer Res 2012 18 2658 2667 10.1158/1078-0432.CCR-11-1900 22421192
68. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D, Int J Cancer 2011 129 245 255 10.1002/ijc.25864 21170960
69. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E, Clin Cancer Res 2008 14 6146 6153 10.1158/1078-0432.CCR-08-0509 18829493
70. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J, Mol Cancer Ther 2010 9 369 378 10.1158/1535-7163.MCT-09-0472 20103604
71. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM, Clin Cancer Res 2003 9 327 337 12538485
72. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F, Cancer Res 2000 60 2178 2189 10786682
73. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C, Marmé D, Cancer Res 2000 60 4819 4824 10987292
74. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST, Cancer Res 2005 65 3691 3699 10.1158/0008-5472.CAN-04-3462 15867364
75. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E, J Clin Oncol 2003 21 60 65 10.1200/JCO.2003.10.066 12506171
76. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F, N Engl J Med 2004 350 2335 2342 10.1056/NEJMoa032691 15175435
77. ROM: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, J Clin Oncol 2007 25 1539 1544 10.1200/JCO.2006.09.6305 17442997
78. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J, J Clin Oncol 2008 26 2013 2019 Erratum in: J Clin Oncol 2008, 26:3110. J Clin Oncol 2009, 27: 653. 10.1200/JCO.2007.14.9930 18421054
79. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M, J Clin Oncol 2008 26 5326 5334 10.1200/JCO.2008.16.3212 18854571
80. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). Arnold D, Andre T, Bennouna J, Sastre J, Osterlund PJ, Greil R, Van Cutsem E, Von Moos R, Reyes-Rivera I, Bendahmane B, Kubicka S, J Clin Oncol 2012 30 suppl RA3503
81. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Wagner A, Laurent D, Grothey A, on behalf of CORRECT Investigators, J Clin Oncol 2012 30 suppl 3502
82. Addition of aflibercept to FOLFIRI improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, Van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C, J Clin Oncol 2012 10.1200/JCO.2012.42.8201
83. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. Allegra CJ, Lakomy R, Tabernero J, Prausová J, Ruff P, Van Hazel G, Moiseyenko VM, Ferry DR, McKendrick JJ, Van Cutsem E, J Clin Oncol 2012 30 suppl 3505
84. Exploration of the effect of treatment to progression with the VEGF signaling inhibitor cediranib (CED) plus chemotherapy (CT) on the results of the HORIZON (HZ) II trial in first-line metastatic colorectal cancer. Fielding A, Hoff PM, Pike L, Wilson D, Robertson JD, J Clin Oncol 2011 29 suppl 14052
85. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw WS, Sawyer MB, Jefford M, Magoski NM, Haydon AM, Walters IB, Tu D, O'Callaghan CJ, NCIC Clinical Trials Group and AGITG, J Clin Oncol 2012 30 suppl 4 3504